When a motion for summary judgment presents complex legal issues with far-reaching implications, a judge must balance two competing goals. Confronted with the prospect of lengthy pre-trial proceedings that postpone the day of judgment, the district court must conserve judicial resources by рromptly resolving those matters in which “no genuine issue as to any material fact” is presented. Fed.R.Civ.P. 56(c). At the same time, justice requires careful consideration of the entire posture of the case so the “drastic device” of summary judgment,
Heyman
v.
Commerce and Industry Co.,
In its understandable zeal to resolve non-perspicuous issues of interpretation, a district court may at times lose sight of the need for restraint. Justice must be both rapid and fair. Matters which our system of conflict resolution reserves for full exposition at trial may not be consigned to cursory disposition. This Court has on numerous occasions set forth the standards whiсh judges must follow in deciding whether to grant summary judgment.
See, e.g., Quinn v. Syracuse Model Neighborhood Corp.,
To facilitate understanding of the issues raised for our consideration, we set forth the facts in some detail, mindful that ambiguities must be resolved and reasonable inferences drawn in favor of the party against whom summary judgment is sought.
Heyman v. Commerce and Industry Co., supra,
I
This controversy arose from a dispute between Schering Corporation (“Schering”), a drug manufacturer, and its excess liability insurer, Home Insuranсe Company (“Home”). At stake is Home’s potential liability for untold millions of dollars in payment for claims by plaintiffs who assert injury from Schering’s synthetic estrogen product, dienestrol (“DEN”). The story of DEN is a tragic tale of modern medicine as well as a word of caution to insurers to anticipate potentiаl problems created by unscrutinized standard clauses in policies.
In 1958, Schering commenced the manufacture and distribution of DEN either directly or through a subsidiary. Synthetic estrogens such as DEN and its chemical cousin, the well-known diethylstilbesterol (“DES”), have been prescribed to women since the early 1940’s for a variety of reasons. In particular, DEN was widely administered to patients with high-risk pregnancies for the purpose of preventing miscarriages.
While thousands of doctors were dispensing synthetic estrogens to millions of expectant mothers, Schering and Home entered into an important series of cоntracts. From August 30, 1966 to February 7, 1976, Schering paid Home over $1,000,000 in premiums for excess liability coverage. Unable to anticipate the tidal wave of controversy, anguish, and, finally, litigation, that would soon inundate the makers and users of both DES and DEN, Schering and its insurer concluded standard-form comprehensive general liability (“CGL”) contracts. The critical provision of this type of policy is the stipulation that the insurer agreed to indemnify the manufacturer for liability when use of its products resulted in personal injury during the policy period. The pertinent language is set forth in the margin. 1
In 1971, an association between synthetic estrogens and clear-cell vaginal adenocarcinoma (a cancer of glandular tissues in the vagina) in daughters of women who had taken DES was reported in the medical literature. Herbst, Ulfelder & Poskanzer, Adenocarcinoma of the Vagina, 284 New England J.Med. 878 (1971). Later that year, the Food and Drug Administration (FDA) proscribed the use of DEN (as well as DES) in the treаtment of pregnant women. Although DES and DEN continue to be marketed for purposes other than preventing miscarriages, their deleterious effects on female offspring of women who took the drugs while with child (commonly referred to as “DES daughters”) are well documented. Since the initial study and FDA banning order, maternal ingestion has been associated with adenosis (abnormal presence of glandular epithelial cells or tissue in the vagina or cervix), structural abnormalities of the cervix and vagina, surgical interventions such as vaginectomies, and a host of other afflictions (infertility, anxiety, embarrassment, mental anguish, and other psychological sequela).
II
Schering initially sought a declaratory judgment pursuant to 28 U.S.C. § 2201 for a statement of its rights under the insurance policies. On May 6, 1980, the trial court approved a stipulation in which the parties agreed to dismissal of Schering’s complaint without prejudice. The action procеeded on counterclaims filed on January 16, 1980 by Home. The litigation was to resolve, inter alia, the issue whether Home was obligated to defend or indemnify Schering for any loss from prenatal use of DEN “which resulted, was discovered or became manifest” during the policy period. Schering’s motion for summary judgment was filed November 10, 1980.
Appellee’s original contention was that the proper interpretation of the key words “results in personal injury ... during the policy period” required appellant to indemnify Schering for losses sustained from claims for injuries which became manifest during the policy period. But, the injuries to daughters of DES users become manifest only some years after the onset of menses, when the ill-fated offspring mature and discover the extent of the damage visited upon them.
During the pendency of the action a
deus ex machina
in the form of an opinion of the District of Columbia Circuit persuaded Schering to modify its theory. In
Keene Corp. v. Insurance Co. of North America,
Finding this logic unassailable, Schering abandoned its “manifestation” theory and urged the district court to find that “each insurer on the risk from initial exposure to manifestаtion is liable for full indemnification.” Schering Corp.’s Summary Memorandum In Support of Its Motion For Summary Judgment. Home submitted affidavits in support of its counter-argument that the parties intended coverage to commence when the injury to DES daughters occurred (presumably while tort plaintiffs were en ventre sa mere, often before 1966).
The district court rejected both appellant’s and appellee’s theories. The court did grant Schering summary judgment, however, concluding the CGL terms require Home to indemnify its insured for liability arising from injuries which occurred either at the time DEN was ingested (origination of injury) or when injury was discovered by DES daughters (manifestation of injury).
We shall not attempt to untangle this Gordian knot of interpretation. The day of reckoning on these important issues must await full development of relevant, material, and competent evidence. As we noted, the trial court had before it conflicting allegations in affidavits submitted in support of and in opposition to the motion. Moreover, the trial court stayed appellee’s motion for further discovery.
Ill
We have stated that “on a motion for summary judgment the court cannot try issues of fact; it can only determine whether there are issues to be tried.”
Heyman v. Commerce and Industry Co., supra,
The moving party has the burden of demonstrating the absence of any material factual issue genuinely in dispute,
Quinn
v.
Syracuse Model Neighborhood Corp., supra,
The summary judgment principles elucidated in
Heyman, supra
and our other cases require that where contract language is susceptible of at least two fairly reasonable meanings, the parties have a right to present extrinsic evidence of their intent at the time of contracting. Summary judgment is perforce improper if conflicting evidence is adduced.
Id.
at 1320;
Home Insurance Co. v. Aetna Casualty & Surety Co., supra,
Home submitted affidavits of the drafters of the industry-wide standardized CGL clause asserting an explication completely at variance from Schering’s construction of the contract. George Katz and Richard A. Schmalz both claimed that, as draftsmen, they contemplated coverage for injuries which occur, rather than became manifest, during the policy period.
See
Affidavit of George Katz and Affidavit of Richard A. Schmalz. Home’s theory was clearly neither frivolous nor meritless. Accordingly, the court below was obligated to identify the disputed issue of intended meaning rather than to resolve it.
Quinn v. Syracuse Model Neighborhood Corp., supra,
Moreover, we have frequently emphasized the critical importance of discovery in the summary judgment context. Home sought evidence demonstrating Schering accepted, adopted, or otherwise ratified the elucidation of the contracts set forth in the drafters’ affidavits. From an evidently well-intentioned desire to resolve this troublesome litigation exрeditiously, the trial court stayed this discovery, basing its action on the fact Schering had already produced 74,000 pages of documents and on its understanding that Home, as a party to the contract, had ample knowledge of intent.
Home’s request for additional documents was neither quixotic nor superfluous. Schering’s responses to Home’s previous demands were deficient in many respects. The manufacturer furnished cover letters with tantalizing references to attachments probative of the insured’s understanding, but withheld the attachments. That Home was a party to original negotiations with appellee is not dispositive. Evidence of contractual intent is typically within the exclusive control of the party whose state of mind is at issue, and the insurer was in no position to demonstrate what its insured's understanding might have been, based only upon its own files. As we have previously cautioned, “summary judgment is likely to be inappropriate when the issues concern intent.”
SEC v. Research Automation Corp., supra,
We have held where a contract is not wholly unambiguous, summary judgment must be denied even where bоth parties move for pre-trial resolution.
Home Insurance Co. v. Aetna Casualty & Surety Co., supra,
Accordingly, we reverse the judgment and remand for further proceedings. Our
Notes
. In relevant part, Home’s CGL policies state: 1. Coverage
The Company hereby agrees ... to indemnify the Insured for all sums which the Insured shall be obligated to pay ... for damages, direct or consequential and expenses ... on account of:
(i) Personal Injuries, including death at any time resulting therefrom, ... caused by or arising out of еach occurrence happening anywhere in the world.
See, e.g., Home Insurance Company policy number HEC 4429288, Insuring Agreements, at para. 1.
. The court below attempted to dispose of the matter of conflicting interpretation by applying the accepted maxim requiring ambiguities in insurance contracts to be construed against the insurer.
Moreover, there is an unresolved question whether the rule of
contra preferentem
is even applicable in a situation involving a large, sophisticated, counselled entity such as Schering, since a number оf courts have recognized that in cases involving bargained-for contracts, negotiated by sophisticated parties, the underlying adhesion contract rationale for the doctrine is inapposite.
See, e.g., Eagle Leasing Corp. v. Hartford Fire Ins. Co.,
540F.2d 1257, 1261 (5th Cir.1976), cert.
denied,
